The Swine Flu and Bird Flu Stocks Index was the top performing tickerspy Index on the day, led by Hemispherx BioPharma (AMEX: HEB - News) with a 33% gain.
又出了一篇叫好的股评。
heb已经收到日本、奥地利、意大利三个国家政府的邀请,对抗猪流感了。
The acceptance by the Italian government (and the Japanese and Australian governments) of its flu vaccine adjuvant would indicate that HEB is indeed a serious player with leading edge technology. This leads one to believe that the prospects for FDA approval of HEB's ampligen drug are good. Just the positive publicity from the flu acclaim is bound to sway the FDA a little. This story may get better soon. The FDA would not have requested more time, if they were definitely going to reject HEB's NDA. That puts the odds at considerably better than 50% for acceptance.